These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33645386)

  • 1. Evaluating brexanolone for the treatment of postpartum depression.
    Payne JL
    Expert Opin Pharmacother; 2021 Jun; 22(8):959-964. PubMed ID: 33645386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brexanolone to Treat Postpartum Depression in Adult Women.
    Cornett EM; Rando L; Labbé AM; Perkins W; Kaye AM; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2021 Mar; 51(2):115-130. PubMed ID: 34092826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brexanolone for postpartum depression.
    Hutcherson TC; Cieri-Hutcherson NE; Gosciak MF
    Am J Health Syst Pharm; 2020 Feb; 77(5):336-345. PubMed ID: 32073124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression.
    Kanes SJ; Colquhoun H; Doherty J; Raines S; Hoffmann E; Rubinow DR; Meltzer-Brody S
    Hum Psychopharmacol; 2017 Mar; 32(2):. PubMed ID: 28370307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.
    Meltzer-Brody S; Colquhoun H; Riesenberg R; Epperson CN; Deligiannidis KM; Rubinow DR; Li H; Sankoh AJ; Clemson C; Schacterle A; Jonas J; Kanes S
    Lancet; 2018 Sep; 392(10152):1058-1070. PubMed ID: 30177236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brexanolone for the treatment of patients with postpartum depression.
    Morrison KE; Cole AB; Thompson SM; Bale TL
    Drugs Today (Barc); 2019 Sep; 55(9):537-544. PubMed ID: 31584571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations.
    Leader LD; O'Connell M; VandenBerg A
    Pharmacotherapy; 2019 Nov; 39(11):1105-1112. PubMed ID: 31514247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on approved and emerging drugs for the treatment of postpartum depression.
    Çulcu EA; Demiryürek Ş; Demiryürek AT
    Ideggyogy Sz; 2024 Jul; 77(7-8):227-235. PubMed ID: 39082257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [GABAergic approach of postpartum depression: A translational review of literature].
    Verbe J; Dubertret C; El-Hage W; Bonnet-Brilhault F; Duriez P
    Encephale; 2020 Apr; 46(2):123-134. PubMed ID: 31767256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and clinical pharmacology of brexanolone (allopregnanolone) for postpartum depression: a landmark journey from concept to clinic in neurosteroid replacement therapy.
    Reddy DS; Mbilinyi RH; Estes E
    Psychopharmacology (Berl); 2023 Sep; 240(9):1841-1863. PubMed ID: 37566239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brexanolone For Postpartum Depression: A Novel Approach and a Call for Comprehensive Postpartum Care.
    Jarman AF; MacLean JV; Barron RJ; Wightman RS; McGregor AJ
    Clin Ther; 2020 Jan; 42(1):231-235. PubMed ID: 31910998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brexanolone: A Novel Drug for the Treatment of Postpartum Depression.
    Patatanian E; Nguyen DR
    J Pharm Pract; 2022 Jun; 35(3):431-436. PubMed ID: 33302791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.
    Frieder A; Fersh M; Hainline R; Deligiannidis KM
    CNS Drugs; 2019 Mar; 33(3):265-282. PubMed ID: 30790145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression.
    Powell JG; Garland S; Preston K; Piszczatoski C
    Ann Pharmacother; 2020 Feb; 54(2):157-163. PubMed ID: 31476884
    [No Abstract]   [Full Text] [Related]  

  • 15. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.
    Kanes S; Colquhoun H; Gunduz-Bruce H; Raines S; Arnold R; Schacterle A; Doherty J; Epperson CN; Deligiannidis KM; Riesenberg R; Hoffmann E; Rubinow D; Jonas J; Paul S; Meltzer-Brody S
    Lancet; 2017 Jul; 390(10093):480-489. PubMed ID: 28619476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
    Walkery A; Leader LD; Cooke E; VandenBerg A
    Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies.
    Zheng W; Cai DB; Zheng W; Sim K; Ungvari GS; Peng XJ; Ning YP; Wang G; Xiang YT
    Psychiatry Res; 2019 Sep; 279():83-89. PubMed ID: 31323375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brexanolone: First Global Approval.
    Scott LJ
    Drugs; 2019 May; 79(7):779-783. PubMed ID: 31006078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of neuroactive steroids for the treatment of postpartum depression.
    Gunduz-Bruce H; Takahashi K; Huang MY
    J Neuroendocrinol; 2022 Feb; 34(2):e13019. PubMed ID: 34462985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of a Hospital-based Brexanolone Program.
    Howard MM; Diaz Z; Battle CL
    J Psychiatr Pract; 2022 Sep; 28(5):404-408. PubMed ID: 36074110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.